OrthoPediatrics Corp. (“OrthoPediatrics” or the
“Company”) (Nasdaq: KIDS), a company focused exclusively on
advancing the field of pediatric orthopedics, today announced its
financial results for the first quarter ended March 31, 2023.
First Quarter
2023 and Business Highlights
- Helped over 19,000 children in the
first quarter of 2023, bringing the total to almost 650,000 since
inception including MD Orthopedics (“MD Ortho”) and Pega
Medical
- Generated total revenue of $31.6
million for the first quarter of 2023, up 35% from $23.4 million in
first quarter 2022; domestic revenue increased 31% and
international revenue increased 49% in the quarter
- Grew worldwide Trauma &
Deformity revenue 42%, worldwide Scoliosis revenue 18%; Sports
Medicine/Other revenue increased 22% in the first quarter of 2023
compared to the first quarter of 2022
- Received two FDA 510(k) clearances
and launched five new line extensions during the first quarter of
2023
- Increased full year 2023 revenue
guidance to $148.0 million to $151.0 million from just over $146.0
million to $149.0 million, representing growth of 21% to 23%
compared to prior year
David Bailey, President & CEO of
OrthoPediatrics, commented, “I am extremely proud of our team and
our ability to deliver better than expected overall growth to start
the year off strong as the demand at children’s hospitals
normalizes and they continue to manage staffing constraints. As we
continue to develop and launch new products, we are seeing
increased adoption of our product offering driving meaningful
market share gains. Overall, I am very pleased with our progress
and believe we are well-positioned strategically to continue our
successful growth story."
First Quarter
2023 Financial ResultsTotal
revenue for the first quarter of 2023 was $31.6 million, a 35%
increase compared to $23.4 million for the same period last year.
The increase in revenue in the first quarter of 2023 includes $4.8
million of revenue contribution from MD Ortho and Pega Medical.
U.S. revenue for the first quarter of 2023 was $23.8 million, a 31%
increase compared to $18.2 million for the same period last year,
representing 75% of total revenue. The increase in revenue in the
first quarter of 2023 was driven primarily by organic growth in
Trauma and Deformity and Scoliosis products as well as the addition
of MD Ortho and Pega Medical. International revenue for the first
quarter of 2023 was $7.8 million, a 49% increase compared to $5.2
million for the same period last year, representing 25% of total
revenue. Growth in the quarter was primarily driven by the addition
of MD Ortho and Pega Medical as well as increased procedure
volumes.
Trauma and Deformity revenue for the first
quarter of 2023 was $23.4 million, a 42% increase compared to $16.5
million for the same period last year. This growth was driven
primarily by growth across numerous product lines, specifically
Cannulated Screws, PNP Femur and PediPlate systems, coupled with
growth from MD Ortho and Pega Medical. Scoliosis revenue was $7.1
million, an 18% increase compared to $6.0 million for the first
quarter of 2022. Segment growth was driven primarily by increased
domestic sales offset by lower set sales to international stocking
distributors. Sports Medicine/Other revenue for the first quarter
of 2023 was $1.1 million, a 22% increase compared to $0.9 million
for the same period last year.
Gross profit for the first quarter of 2023 was
$23.6 million, a 27% increase compared to $18.6 million for the
same period last year. Gross profit margin for the first quarter of
2023 was 75%, compared to 79% for the same period last year. The
change in gross margin was primarily driven by favorable purchase
price variances in the three months ended March 31, 2022 which did
not repeat in the three months ended March 31, 2023.
Total operating expenses for the first quarter
of 2023 were $32.2 million, a 29% increase compared to $25.0
million for the same period last year. The increase was mainly
driven by the addition of MD Ortho and Pega Medical as well as
incremental personnel required to support the ongoing growth of the
Company.
Sales and marketing expenses increased $2.5
million, or 25%, to $12.2 million in the first quarter of 2023. The
increase was driven primarily by increased sales commission
expenses coupled with additional expenses from recent
acquisitions.
General and administrative expenses increased
$4.5 million, or 34%, to $17.7 million in the first quarter of
2023. The increase was driven primarily by the addition of
personnel and resources to support the continued expansion of the
business and an increase in travel expenses and acquisition related
expenses.
Total other income was $1.2 million for the first quarter of
2023, compared to $3.0 million of other expenses for the same
period last year. The change was due primarily to the fair value
adjustment of contingent consideration, which was driven by the
valuation inputs that were lower in comparison to the same period
last year, resulting in income rather than expense.
Net loss for the first quarter of 2023 was $6.8
million, compared to $9.1 million for the same period last year.
Net loss per share for the period was $0.30 per basic and diluted
share, compared to $0.47 per basic and diluted share for the same
period last year.
Adjusted EBITDA for the first quarter of 2023
was a loss of $2.1 million as compared to a loss of $1.6 million
for the first quarter of 2022.
Weighted average basic and diluted shares
outstanding for the three months ended March 31, 2023, was
22,506,024 shares.
As of March 31, 2023, cash, cash equivalents, short-term
investments and restricted cash were $109.2 million compared to
$119.8 million and $46.4 million as of December 31, 2022, and
March 31, 2022, respectively. Additionally, the Company had no
balance outstanding under the $50.0 million line of credit.
Full Year 2023
Financial GuidanceFor the full year of 2023, the
Company increased its revenue guidance to be in the range of $148.0
million to $151.0 million, representing growth of 21% to 23% over
2022 revenue. The guidance assumes roughly $7.0 million of combined
revenue contribution from MD Ortho and Pega Medical before the
acquisitions become organic on their anniversaries. The Company
reiterated annual set deployment of approximately $25.0 million and
reiterated $3.0 million to $4.0 million of adjusted EBITDA for the
full year of 2023.
Conference CallOrthoPediatrics
will host a conference call on Tuesday, May 2, 2023, at 8:00 a.m.
ET to discuss the results. Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.orthopediatrics.com, on the Investors page in
the Events & Presentations section. The webcast will be
available for replay for at least 90 days after the event.
Forward-Looking StatementsAll
statements, other than statements of historical facts, contained in
this quarterly report, including statements regarding our business,
operations and financial performance and condition, as well as our
plans, objectives and expectations for our business, operations and
financial performance and condition, are forward-looking
statements. You can often identify forward-looking statements by
words such as "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "might," "target,"
"ongoing," "plan," "potential," "predict," "project," "should,"
"will" or "would," or the negative of these terms or other terms.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors, such as the impact of widespread
health emergencies, such as COVID 19 and respiratory syncytial
virus, that may cause our results, activity levels, performance or
achievements to be materially different from the information
expressed or implied by the forward-looking statements.
Forward-looking statements may include, among other things,
statements relating to: our ability to achieve or sustain
profitability in the future; our ability to raise additional
capital to fund our existing commercial operations, develop and
commercialize new products and expand our operations; our ability
to commercialize our products in development and to develop and
commercialize additional products through our research and
development efforts, and if we fail to do so we may be unable to
compete effectively; our ability to generate sufficient revenue
from the commercialization of our products to achieve and sustain
profitability; our ability to comply with extensive government
regulation and oversight both in the United States and abroad; our
ability to maintain and expand our network of third-party
independent sales agencies and distributors to market and
distribute our products; and our ability to protect our
intellectual property rights or if we are accused of infringing on
the intellectual property rights of others; We cannot assure you
that forward-looking statements will prove to be accurate, and you
are encouraged not to place undue reliance on forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations expressed or implied by the
forward-looking statements. You are urged to carefully review and
consider the various disclosures made by us in this quarterly
report, in our Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the "SEC") on March 1, 2023 and in other
reports filed with the SEC that discuss the risks and factors that
may affect our business. Other than as required by law, we
undertake no obligation to update or revise any forward-looking
statements to reflect new information, events or circumstances
occurring after the date of this quarterly report.
Use of Non-GAAP Financial
MeasuresThis press release includes certain non-GAAP
financial measures such as organic revenue, adjusted diluted
earnings (loss) per share and Adjusted EBITDA, which differ from
financial measures calculated in accordance with U.S. generally
accepted accounting principles (“GAAP”). Sales on an organic basis
excludes from our reported net revenue growth the impacts of
revenue from any acquired business that have been owned for less
than one year. We believe that providing the non-GAAP organic
revenue is useful as a way to measure and evaluate our underlying
performance consistently across the periods presented. Adjusted
earnings (loss) per share in this press release represents diluted
earnings (loss) per share on a GAAP basis, plus the accreted
interest attributable to acquisition installment payables, the fair
value adjustment of contingent consideration, trademark impairment,
acquisition related costs, non-recurring professional fees, accrued
legal settlement costs and minimum purchase commitment costs. The
fair value adjustment of contingent consideration is associated
with our estimates of the value of earn-outs in connection with
certain acquisitions and the non-recurring professional fees are
related to our response to a previously disclosed SEC review. We
believe that providing the non-GAAP diluted earnings (loss) per
share excluding these expenses, as well as the GAAP measures,
assists our investors because such expenses are not reflective of
our ongoing operating results. Adjusted EBITDA in this release
represents net loss, plus interest expense, net plus other expense,
provision for income taxes (benefit), depreciation and
amortization, trademark impairment, stock-based compensation
expense, fair value adjustment of contingent consideration,
acquisition related costs, nonrecurring professional fees, accrued
legal settlements costs, and the cost of minimum purchase
commitments. The Company believes the non-GAAP measures provided in
this earnings release enable it to further and more consistently
analyze the period-to-period financial performance of its core
business operating performance. Management uses these metrics as a
measure of the Company’s operating performance and for planning
purposes, including financial projections. The Company believes
these measures are useful to investors as supplemental information
because they are frequently used by analysts, investors and other
interested parties to evaluate companies in its industry. Adjusted
EBITDA is a non-GAAP financial measure and should not be considered
as an alternative to, or superior to, net income or loss as a
measure of financial performance or cash flows from operations as a
measure of liquidity, or any other performance measure derived in
accordance with GAAP, and it should not be construed to imply that
the Company’s future results will be unaffected by unusual or
non-recurring items. In addition, the measure is not intended to be
a measure of free cash flow for management’s discretionary use, as
it does not reflect certain cash requirements such as debt service
requirements, capital expenditures and other cash costs that may
recur in the future. Adjusted EBITDA contains certain other
limitations, including the failure to reflect our cash
expenditures, cash requirements for working capital needs and other
potential cash requirements. In evaluating these non-GAAP measures,
you should be aware that in the future the Company may incur
expenses that are the same or similar to some of the adjustments in
this presentation. The Company’s presentation of non-GAAP diluted
earnings (loss) per share or Adjusted EBITDA should not be
construed to imply that its future results will be unaffected by
any such adjustments. Management compensates for these limitations
by primarily relying on the Company’s GAAP results in addition to
using these adjusted measures on a supplemental basis. The
Company’s definition of these measures is not necessarily
comparable to other similarly titled captions of other companies
due to different methods of calculation. The schedules below
contain reconciliations of reported GAAP net revenue to non-GAAP
organic revenue, GAAP diluted earnings (loss) per share to non-GAAP
diluted earnings (loss) and net loss to non-GAAP Adjusted
EBITDA.
About OrthoPediatrics
Corp.Founded in 2006, OrthoPediatrics is an orthopedic
company focused exclusively on advancing the field of pediatric
orthopedics. As such it has developed the most comprehensive
product offering to the pediatric orthopedic market to improve the
lives of children with orthopedic conditions. OrthoPediatrics
currently markets 48 surgical systems that serve three of the
largest categories within the pediatric orthopedic market. This
product offering spans trauma and deformity, scoliosis, and sports
medicine/other procedures. OrthoPediatrics’ global sales
organization is focused exclusively on pediatric orthopedics and
distributes its products in the United States and over 70 countries
outside the United States. For more information, please visit
www.orthopediatrics.com.
Investor ContactPhilip Trip TaylorGilmartin
Groupphilip@gilmartinir.com415-937-5406
ORTHOPEDIATRICS CORP. |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(Unaudited) |
(In Thousands, Except Share Data) |
|
|
March 31, 2023 |
|
December 31, 2022 |
|
|
|
|
ASSETS |
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
34,656 |
|
|
$ |
8,991 |
|
Restricted cash |
|
1,481 |
|
|
|
1,471 |
|
Short term investments |
|
73,074 |
|
|
|
109,299 |
|
Accounts receivable - trade, net of allowances of $942 and $1,056,
respectively |
|
26,838 |
|
|
|
24,800 |
|
Inventories, net |
|
84,922 |
|
|
|
78,192 |
|
Prepaid expenses and other current assets |
|
4,005 |
|
|
|
3,966 |
|
Total current assets |
|
224,976 |
|
|
|
226,719 |
|
|
|
|
|
Property and equipment,
net |
|
36,916 |
|
|
|
34,286 |
|
|
|
|
|
Other assets: |
|
|
|
Amortizable intangible assets, net |
|
64,642 |
|
|
|
64,980 |
|
Goodwill |
|
84,127 |
|
|
|
86,821 |
|
Other intangible assets |
|
15,629 |
|
|
|
14,921 |
|
Total other assets |
|
164,398 |
|
|
|
166,722 |
|
|
|
|
|
Total assets |
$ |
426,290 |
|
|
$ |
427,727 |
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
Current liabilities: |
|
|
|
Accounts payable - trade |
|
16,692 |
|
|
|
11,150 |
|
Accrued compensation and benefits |
|
6,242 |
|
|
|
6,744 |
|
Current portion of long-term debt with affiliate |
|
146 |
|
|
|
144 |
|
Current portion of acquisition installment payable |
|
8,000 |
|
|
|
7,815 |
|
Other current liabilities |
|
4,138 |
|
|
|
5,018 |
|
Total current liabilities |
|
35,218 |
|
|
|
30,871 |
|
|
|
|
|
Long-term liabilities: |
|
|
|
Long-term debt with affiliate, net of current portion |
|
725 |
|
|
|
763 |
|
Acquisition installment payment, net of current portion |
|
8,215 |
|
|
|
8,019 |
|
Contingent consideration |
|
2,310 |
|
|
|
2,980 |
|
Deferred income taxes |
|
6,022 |
|
|
|
5,954 |
|
Other long-term liabilities |
|
645 |
|
|
|
492 |
|
Total long-term liabilities |
|
17,917 |
|
|
|
18,208 |
|
|
|
|
|
Total liabilities |
|
53,135 |
|
|
|
49,079 |
|
|
|
|
|
Stockholders' equity: |
|
|
|
Common stock, $0.00025 par value; 50,000,000 shares authorized;
23,142,118 shares and 22,877,962 shares issued as of March 31,
2023 and December 31, 2022, respectively |
|
6 |
|
|
|
6 |
|
Additional paid-in capital |
|
562,769 |
|
|
|
560,810 |
|
Accumulated deficit |
|
(183,574 |
) |
|
|
(176,768 |
) |
Accumulated other comprehensive loss |
|
(6,046 |
) |
|
|
(5,400 |
) |
Total stockholders' equity |
|
373,155 |
|
|
|
378,648 |
|
|
|
|
|
Total liabilities and
stockholders' equity |
$ |
426,290 |
|
|
$ |
427,727 |
|
|
|
|
|
|
|
|
|
ORTHOPEDIATRICS CORP. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(Unaudited) |
(In Thousands, Except Share and Per Share
Data) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Net revenue |
$ |
31,588 |
|
|
$ |
23,417 |
|
Cost of revenue |
|
8,027 |
|
|
|
4,851 |
|
Gross profit |
|
23,561 |
|
|
|
18,566 |
|
|
|
|
|
Operating expenses: |
|
|
|
Sales and marketing |
|
12,216 |
|
|
|
9,758 |
|
General and administrative |
|
17,666 |
|
|
|
13,167 |
|
Research and development |
|
2,270 |
|
|
|
2,027 |
|
Total operating expenses |
|
32,152 |
|
|
|
24,952 |
|
|
|
|
|
Operating loss |
|
(8,591 |
) |
|
|
(6,386 |
) |
|
|
|
|
Other (income) expenses: |
|
|
|
Interest (income) expense, net |
|
(210 |
) |
|
|
566 |
|
Fair value adjustment of contingent consideration |
|
(670 |
) |
|
|
2,570 |
|
Other income |
|
(331 |
) |
|
|
(105 |
) |
Total other (income) expenses |
|
(1,211 |
) |
|
|
3,031 |
|
|
|
|
|
Loss before income taxes |
$ |
(7,380 |
) |
|
$ |
(9,417 |
) |
Provision for income taxes
(benefit) |
|
(574 |
) |
|
|
(317 |
) |
Net loss |
$ |
(6,806 |
) |
|
$ |
(9,100 |
) |
Weighted average common stock
- basic and diluted |
|
22,506,024 |
|
|
|
19,366,911 |
|
Net loss per share – basic and
diluted |
$ |
(0.30 |
) |
|
$ |
(0.47 |
) |
ORTHOPEDIATRICS
CORP.CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS(Unaudited)(In Thousands)
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
OPERATING ACTIVITIES |
|
Net loss |
$ |
(6,806 |
) |
|
$ |
(9,100 |
) |
Adjustments to reconcile net
loss to net cash used in operating activities: |
|
|
|
Depreciation and amortization |
|
3,848 |
|
|
|
2,961 |
|
Stock-based compensation |
|
2,113 |
|
|
|
1,526 |
|
Fair value adjustment of contingent consideration |
|
(670 |
) |
|
|
2,570 |
|
Accretion of acquisition installment payable |
|
381 |
|
|
|
453 |
|
Deferred income taxes |
|
(574 |
) |
|
|
(317 |
) |
Changes in certain current assets and liabilities: |
|
|
|
Accounts receivable - trade |
|
(2,002 |
) |
|
|
2 |
|
Inventories |
|
(5,979 |
) |
|
|
(6,750 |
) |
Prepaid expenses and other current assets |
|
(33 |
) |
|
|
112 |
|
Accounts payable - trade |
|
5,541 |
|
|
|
5,258 |
|
Accrued expenses and other liabilities |
|
(1,571 |
) |
|
|
(690 |
) |
Other |
|
(709 |
) |
|
|
(222 |
) |
Net cash used in operating
activities |
|
(6,461 |
) |
|
|
(4,197 |
) |
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
Sale of short-term marketable
securities |
|
37,250 |
|
|
|
18,500 |
|
Purchases of property and
equipment |
|
(4,940 |
) |
|
|
(4,197 |
) |
Net cash provided by investing
activities |
|
32,310 |
|
|
|
14,303 |
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
Payments on mortgage
notes |
|
(36 |
) |
|
|
(33 |
) |
Net cash used in financing
activities |
|
(36 |
) |
|
|
(33 |
) |
|
|
|
|
Effect of exchange rate
changes on cash, cash equivalents and restricted cash |
|
(138 |
) |
|
|
241 |
|
|
|
|
|
NET INCREASE IN CASH, CASH
EQUIVALENTS AND RESTRICTED CASH |
|
25,675 |
|
|
|
10,314 |
|
|
|
|
|
Cash, cash equivalents and
restricted cash, beginning of period |
$ |
10,462 |
|
|
$ |
9,006 |
|
Cash, cash equivalents and
restricted cash, end of period |
$ |
36,137 |
|
|
$ |
19,320 |
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES |
|
|
|
Cash paid for interest |
$ |
11 |
|
|
$ |
13 |
|
Transfer of instruments from
property and equipment to inventory |
$ |
332 |
|
|
$ |
(54 |
) |
ORTHOPEDIATRICS CORP. |
NET REVENUE BY GEOGRAPHY AND PRODUCT CATEGORY |
(Unaudited) |
(In Thousands) |
|
|
Three Months Ended March 31, |
Product sales by geographic location: |
|
2023 |
|
|
2022 |
U.S. |
$ |
23,800 |
|
$ |
18,188 |
International |
|
7,788 |
|
|
5,229 |
Total |
$ |
31,588 |
|
$ |
23,417 |
|
|
|
|
|
Three Months Ended March 31, |
Product sales by
category: |
|
2023 |
|
|
2022 |
Trauma and deformity |
$ |
23,395 |
|
$ |
16,516 |
Scoliosis |
|
7,072 |
|
|
5,983 |
Sports medicine/other |
|
1,121 |
|
|
918 |
Total |
$ |
31,588 |
|
$ |
23,417 |
ORTHOPEDIATRICS CORP. |
RECONCILIATION OF NET REVENUE TO NON-GAAP ORGANIC
REVENUE |
(Unaudited) |
(In Thousands) |
|
Three Months Ended March 31, |
Product sales by geographic location: |
|
2023 |
|
|
2022 |
As reported: |
|
|
|
U.S. |
$ |
23,800 |
|
$ |
18,188 |
International |
|
7,788 |
|
|
5,229 |
Less impact from
acquisitions: |
|
|
|
U.S. |
|
2,560 |
|
|
— |
International |
|
2,275 |
|
|
— |
Organic revenue: |
|
|
|
U.S. |
|
21,240 |
|
|
18,188 |
International |
|
5,513 |
|
|
5,229 |
Total organic revenue |
$ |
26,753 |
|
$ |
23,417 |
|
|
|
|
|
Three Months Ended March 31, |
Product sales by
category: |
|
2023 |
|
|
2022 |
As reported: |
|
|
|
Trauma and deformity |
$ |
23,395 |
|
$ |
16,516 |
Scoliosis |
|
7,072 |
|
|
5,983 |
Sports medicine/other |
|
1,121 |
|
|
918 |
Total |
$ |
31,588 |
|
$ |
23,417 |
|
|
|
|
Less: impact from
acquisitions |
|
|
|
Trauma and deformity |
|
4,835 |
|
|
— |
Organic revenue: |
|
|
|
Trauma and deformity |
|
18,560 |
|
|
16,516 |
Scoliosis |
|
7,072 |
|
|
5,983 |
Sports medicine/other |
|
1,121 |
|
|
918 |
Total organic revenue |
$ |
26,753 |
|
$ |
23,417 |
ORTHOPEDIATRICS CORP. |
RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED
EBITDA |
(Unaudited) |
(In Thousands) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Net loss |
$ |
(6,806 |
) |
|
$ |
(9,100 |
) |
Interest (income) expense, net |
|
(210 |
) |
|
|
566 |
|
Other income |
|
(331 |
) |
|
|
(105 |
) |
Provision for income taxes (benefit) |
|
(574 |
) |
|
|
(317 |
) |
Depreciation and amortization |
|
3,848 |
|
|
|
2,961 |
|
Stock-based compensation |
|
2,113 |
|
|
|
1,526 |
|
Fair value adjustment of contingent consideration |
|
(670 |
) |
|
|
2,570 |
|
Acquisition related costs |
|
— |
|
|
|
204 |
|
Nonrecurring Pega conversion fees |
|
277 |
|
|
|
— |
|
Minimum purchase commitment cost |
|
300 |
|
|
|
101 |
|
Adjusted EBITDA |
$ |
(2,053 |
) |
|
$ |
(1,594 |
) |
|
|
ORTHOPEDIATRICS CORP. |
RECONCILIATION OF DILUTED LOSS PER SHARE TO NON-GAAP
ADJUSTED DILUTED LOSS PER SHARE |
(Unaudited) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Loss per share, diluted
(GAAP) |
$ |
(0.30 |
) |
|
$ |
(0.47 |
) |
Accretion of interest attributable to acquisition installment
payable |
|
0.02 |
|
|
|
0.02 |
|
Fair value adjustment of contingent consideration |
|
(0.03 |
) |
|
|
0.13 |
|
Acquisition related costs |
|
— |
|
|
|
0.01 |
|
Nonrecurring Pega conversion fees |
|
0.01 |
|
|
|
— |
|
Minimum purchase commitment cost |
|
0.01 |
|
|
|
0.01 |
|
Loss per share, diluted
(non-GAAP) |
$ |
(0.29 |
) |
|
$ |
(0.30 |
) |
OrthoPediatrics (NASDAQ:KIDS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
OrthoPediatrics (NASDAQ:KIDS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024